Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.5003
-0.0299 (-5.64%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Century Therapeutics Stock Forecast
IPSC's stock price has decreased by -83.1% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Century Therapeutics stock have an average target of 3.67, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 633.56% from the current stock price of 0.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Century Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | +299.76% | Apr 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +1,299.16% | Mar 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +899.40% | Mar 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $2 | Buy | Maintains | $4 → $2 | +299.76% | Mar 20, 2025 |
Financial Forecast
Revenue This Year
61.48M
from 6.59M
Increased by 833.10%
Revenue Next Year
8.03M
from 61.48M
Decreased by -86.94%
EPS This Year
-1.07
from -1.61
EPS Next Year
-1.35
from -1.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 114.7M | 24.8M | 7.8M | ||
| Avg | 61.5M | 8.0M | 7.6M | ||
| Low | 392,000 | n/a | 7.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,640.2% | -59.7% | -2.3% | ||
| Avg | 833.1% | -86.9% | -5.1% | ||
| Low | -94.1% | - | -8.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.28 | -0.67 | -1.24 |
| Avg | -1.07 | -1.35 | -1.20 |
| Low | -1.75 | -1.85 | -1.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.